MYL Mylan NV

By Adria Calatayud

Shares of Indivior PLC (INDV.LN) fell Friday, a day after the U.S. Food and Drug Administration approved generic versions of the company's Suboxone film from both Dr. Reddy's Laboratories Ltd. (500124.BY) and Mylan NV (MYL).

The pharmaceutical company said it will pursue all legal remedies available in the ongoing patent litigation with Dr. Reddy's over Suboxone--a treatment for opioid dependence. Until the details of Dr. Reddy's generic market entry are confirmed, Indivior's guidance for 2018--which assumes no generic competition--remains unchanged, the company said.

The launch of generic alternatives to Suboxone could potentially result in a rapid and material loss of market share for the film in the U.S. within months, Indivior said. The FTSE 250-listed company said it has developed plans for this generic competition.

Indivior shares at 1331 GMT were down 23% at 380.60 pence.

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

(END) Dow Jones Newswires

June 15, 2018 09:47 ET (13:47 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.